Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA.
作者信息
Izzedine Hassane, Massard Christophe, Soria Jean Charles
机构信息
Department of Nephrology, Pitie-Salpetriere Hospital , Université Paris VI , Pierre et Marie Curie, Paris , France.
Department of Medical Oncology, Institut Gustave Roussy, Service des Innovations Thérapeutiques Précoces (SITEP) , Université Paris XI , Ville Juif , France.
出版信息
NDT Plus. 2011 Feb;4(1):78-9. doi: 10.1093/ndtplus/sfq178. Epub 2010 Oct 7.
Abstract
摘要
相似文献
1
Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA.
NDT Plus. 2011 Feb;4(1):78-9. doi: 10.1093/ndtplus/sfq178. Epub 2010 Oct 7.
2
Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma.
Cancer Epidemiol. 2018 Oct;56:118-125. doi: 10.1016/j.canep.2018.08.006. Epub 2018 Aug 30.
3
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
Eur J Cancer. 2015 Nov;51(16):2368-74. doi: 10.1016/j.ejca.2015.07.030. Epub 2015 Aug 11.
4
Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Intern Med J. 2016 Nov;46(11):1291-1297. doi: 10.1111/imj.13202.
5
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.
6
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
Nephrol Dial Transplant. 2009 Feb;24(2):682-5. doi: 10.1093/ndt/gfn657. Epub 2008 Dec 2.
7
The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions.
Curr Opin Urol. 2019 Sep;29(5):531-539. doi: 10.1097/MOU.0000000000000663.
8
Advanced renal cell carcinoma: current and emerging management strategies.
Drugs. 2007;67(9):1257-64. doi: 10.2165/00003495-200767090-00002.
9
Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.
Clin Genitourin Cancer. 2017 Apr;15(2):e229-e238. doi: 10.1016/j.clgc.2016.08.004. Epub 2016 Aug 10.
10
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Eur Urol. 2019 Jan;75(1):111-128. doi: 10.1016/j.eururo.2018.09.016. Epub 2018 Oct 25.
引用本文的文献
1
Thrombotic Microangiopathy Associated with Pazopanib in a Kidney Transplant Recipient.
J Kidney Cancer VHL. 2021 Mar 24;8(1):25-31. doi: 10.15586/jkcvhl.v8i1.161. eCollection 2021.
本文引用的文献
1
Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation.
NDT Plus. 2008 Jun;1(3):154-6. doi: 10.1093/ndtplus/sfn013. Epub 2008 Mar 11.
2
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
J Clin Oncol. 2010 Jun 10;28(17):e284-5; author reply e286-7. doi: 10.1200/JCO.2009.27.1759. Epub 2010 May 3.
3
TTP-HUS associated with sunitinib.
Cancer Res Treat. 2008 Dec;40(4):211-3. doi: 10.4143/crt.2008.40.4.211. Epub 2008 Dec 31.
4
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
Nephrol Dial Transplant. 2009 Feb;24(2):682-5. doi: 10.1093/ndt/gfn657. Epub 2008 Dec 2.
5
Glomerular disease related to anti-VEGF therapy.
Kidney Int. 2008 Dec;74(11):1487-91. doi: 10.1038/ki.2008.256. Epub 2008 Jun 11.
6
VEGF inhibition and renal thrombotic microangiopathy.
N Engl J Med. 2008 Mar 13;358(11):1129-36. doi: 10.1056/NEJMoa0707330.
7
Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.
Ann Oncol. 2007 Oct;18(10):1745-7. doi: 10.1093/annonc/mdm454.
8
Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.
Nat Clin Pract Nephrol. 2007 May;3(5):287-93. doi: 10.1038/ncpneph0476.
9
Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
Lancet Oncol. 2007 Feb;8(2):177-8. doi: 10.1016/S1470-2045(07)70037-2.
10
Thrombotic microangiopathy and anti-VEGF agents.
Nephrol Dial Transplant. 2007 May;22(5):1481-2. doi: 10.1093/ndt/gfl565. Epub 2006 Dec 21.
Zotero 插件